THERAPY DOSSIER · th-7d900271ae02

Recombinant human Neuregulin-1 beta 1 encapsulated in poly(lactic-co-glycolic acid) (PLGA) microparticles

Biologic · ChEMBL not queried for this formulated recombinant protein in this run (time budget); resolved=false reflects absence of a lookup, not a negative result.

Non-drug Suggest a correction

Evidence & regulatory context

Mechanism: ChEMBL not queried for this formulated recombinant protein in this run (time budget); resolved=false reflects absence of a lookup, not a negative result.
Target: Not recorded
Injury models: Spinal cord injury
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 6

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT01439789 ↗PHASE3terminated

Phase III Recombinant Human Neuregulin-1beta in Chronic Systolic Heart Failure

Chronic Heart Failure

Enrolment: 146 · Results not recorded

NCT05949801 ↗PHASE3completed

Phase III Injectable Neucardin on Cardiac Function and Ventricular Remodelling in Chronic Systolic Heart Failure

Chronic Systolic Heart Failure

Enrolment: 202 · Results not recorded

NCT01251406 ↗PHASE2completed

Phase IIa Efficacy/Safety of Recombinant Human Neuregulin-1 (Neucardin) in Stable Chronic Heart Failure

Chronic Heart Failure

Enrolment: 67 · Results not recorded

NCT07221513 ↗PHASE2withdrawn

Phase 2a Open-Label JK07 in Heart Failure and Group 2 Pulmonary Hypertension (RENEU-PH)

HFrEF · HFpEF · Group 2 Pulmonary Hypertension

Enrolment: 0 · Results not recorded

NCT01258387 ↗PHASE1completed

Phase 1 Single Ascending Doses of GGF2 (Glial Growth Factor 2 / Neuregulin 1beta3) in Left Ventricular Dysfunction and Symptomatic Heart Failure

Heart Failure

Enrolment: 40 · Results not recorded

NCT04210375 ↗PHASE1completed

Phase 1 Safety, Tolerability and PK of JK07 (NRG-1 fusion) in Heart Failure With Reduced Ejection Fraction

Heart Failure With Reduced Ejection Fraction

Enrolment: 14 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 28668379 ↗2017Reported benefit

Design and optimization of PLGA microparticles for controlled and local delivery of Neuregulin-1 in traumatic spinal cord injury.

RatSpinal cord injuryUnspecifiedSprague-DawleyFemaleLocal intraspinal injection

Model: Traumatic spinal cord injury

Local intraspinal PLGA-Nrg-1 maintained significantly higher and more prolonged tissue Nrg-1 than intrathecal osmotic pump delivery, preserved oligodendrocytes and axons, and attenuated neuroinflammation and glial scarring.

Extraction: extract · Supplied extraction confidence: 0.65. Machine-extracted fields require source verification.

Loading the evidence…